RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that its U.S. joint venture, ReGenTree LLC, has submitted a letter to the U.S. FDA requesting a pre-BLA meeting pursuant to RGN-259.
November 29, 2021
· 4 min read